PanGenex Corp. is a nutraceutical and dietary supplement developer focused on pursuing business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, the company develops and markets sector-leading, patented or patent-pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products.

Many of the PanGenex’s products are available anywhere without a prescription. Primary products offered by the company include Calci-Clear, LIPIDEME and Omeganol, all of which address Soft Tissue Calcification (STC), an abnormal hardening or thickening of soft tissues (such as arteries). This condition is linked to over half of chronic diseases and currently affects an estimated 196 million Americans, or 60 percent of the U.S. population.

Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. The company’s products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil, and Australia as well as online at

Let us hear your thoughts: PanGenex Corp. Message Board